Project description
Optimising treatment of children diagnosed with inflammatory bowel disease
Inflammatory bowel disease (IBD), an incurable and inflammatory condition of the gastrointestinal tract, affects millions of patients worldwide. Its prevalence is increasing and most alarmingly nearly a quarter of newly diagnosed patients are children. Better ways to diagnose and treat this condition are needed in light of the high cost and ineffectiveness of current treatment options, especially for children. The EU-funded MAGNETO project aims to develop and introduce a theranostic platform for diagnosis and treatment of paediatric IBD. It will capitalise on a combined approach using the discovery of biomarkers, diagnostic nanomaterials and drug delivery system engineering to produce personalised dosage forms, thus improving patient quality of life.
Objective
Inflammatory bowel disease (IBD) is an incurable, inflammatory condition of the gastrointestinal tract (GIT) that affects millions of patients worldwide and places an enormous economic burden on society. Most alarmingly, children account for one quarter of all IBD cases with steadily increasing incidence. Current clinical practices for IBD diagnosis and therapy are demanding and ineffective in terms of treatment outcome, patient compliance and cost and by far not optimized for children. Our aim is to establish a theranostic platform for diagnosis and personalized treatment of pediatric IBD by an interdisciplinary approach bridging discovery of disease biomarkers, nanomaterial and drug delivery system engineering to manufacture of personalized dosage forms.
We will capitalize on scalable and reproducible flame engineering to tailor the properties of superparamagnetic iron oxide nanoparticles (SPION) and achieve functionalities beyond their current use in the clinic. This multifunctional material will serve as contrast agent in magnetic resonance imaging, tracer particle in magnetic particle imaging and for hyperthermia-triggered drug release. Ligands for disease biomarkers identified by global protein quantification will ensure targeted delivery of the theranostic SPION. We will push the frontiers of magnetic bioimaging for non-invasive and accurate diagnosis of IBD to guide stimuli-responsive drug delivery. To optimize the treatment of sick children, we will design personalized oral dosage forms incorporating our targeted drug carriers by additive manufacturing. The nanoengineering approach along with industrially relevant microencapsulation and 3D printing technologies will provide fundamental insight into physicochemical properties that govern the targeted use of nanomaterials in the challenging GIT environment. The outcome of this research will support personalized therapy of pediatric IBD, improving patient quality of life and reduce the healthcare burden.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-COG - Consolidator Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2020-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
751 05 Uppsala
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.